CUED Publications database

Recommendations for biomarker identification and qualification in clinical proteomics

Mischak, H and Allmaier, G and Apweiler, R and Attwood, T and Baumann, M and Benigni, A and Bennett, SE and Bischoff, R and Bongcam-Rudloff, E and Capasso, G and Coon, JJ and D'Haese, P and Dominiczak, AF and Dakna, M and Dihazi, H and Ehrich, JH and Fernandez-Llama, P and Fliser, D and Frokiaer, J and Garin, J and Girolami, M and Hancock, WS and Haubitz, M and Hochstrasser, D and Holman, RR and Ioannidis, JPA and Jankowski, J and Julian, BA and Klein, JB and Kolch, W and Luider, T and Massy, Z and Mattes, WB and Molina, F and Monsarrat, B and Novak, J and Peter, K and Rossing, P and Sánchez-Carbayo, M and Schanstra, JP and Semmes, OJ and Spasovski, G and Theodorescu, D and Thongboonkerd, V and Vanholder, R and Veenstra, TD and Weissinger, E and Yamamoto, T and Vlahou, A (2010) Recommendations for biomarker identification and qualification in clinical proteomics. Science Translational Medicine, 2. ISSN 1946-6234

Full text not available from this repository.

Abstract

Clinical proteomics has yielded some early positive results - the identification of potential disease biomarkers - indicating the promise for this analytical approach to improve the current state of the art in clinical practice. However, the inability to verify some candidate molecules in subsequent studies has led to skepticism among many clinicians and regulatory bodies, and it has become evident that commonly encountered shortcomings in fundamental aspects of experimental design mainly during biomarker discovery must be addressed in order to provide robust data. In this Perspective, we assert that successful studies generally use suitable statistical approaches for biomarker definition and confirm results in independent test sets; in addition, we describe a brief set of practical and feasible recommendations that we have developed for investigators to properly identify and qualify proteomic biomarkers, which could also be used as reporting requirements. Such recommendations should help put proteomic biomarker discovery on the solid ground needed for turning the old promise into a new reality.

Item Type: Article
Subjects: UNSPECIFIED
Divisions: UNSPECIFIED
Depositing User: Unnamed user with email sms67@cam.ac.uk
Date Deposited: 23 Mar 2020 20:03
Last Modified: 15 Apr 2021 03:02
DOI: 10.1126/scitranslmed.3001249